The risk of hospitalization for heart failure was not significantly different during treatment with liraglutide compared to controls in patients with T2D and CVD risk factors and a meta-analysis on the effect of GLP-1 RA found a non-statistical reduced trend toward a reduction in heart failure. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.